Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Keywords breast cancer sarcoma head and neck cancer skin cancer malignant melanoma CAR-T cells chimeric antigen receptor immunotherapy clinical trials reconstructive surgery Background Cancer continues to be the second most common cause of death in the US totaling 1.9 million new cases and 609,360 deaths in the US in 2022.1 About 60% of US cancer patients undergo surgical cancer treatment.2 Peripheral solid tumors (PSTs), such as breast, malignant skin, head and neck cancers, and sarcomas...
Abstract The microbiome is a complex host factor and key determinant of the outcome of antibody-based and cellular immunotherapy. Its postbiotics are a blend of soluble commensal byproducts that are released into the host environment and have been associated with the regulation of immune homeostasis, particularly through impacts on epigenetics and cell signaling.
Abstract Emerging data have highlighted a correlation between microbiome composition and cancer immunotherapy outcome. While commensal bacteria and their metabolites are known to modulate the host environment, contradictory effects and a lack of mechanistic understanding are impeding the translation of microbiome-based therapies into the clinic.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
